SCHEMBL4572575

SCHEMBL4572575

CC(=O)OCC(O)COP(=O)(O)O

nearest known ligand 0.57

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
LPAR1 Q92633 10/20 0.57
LPAR5 Q9H1C0 4/20 0.57
LPAR4 Q99677 3/20 0.57
LPAR2 Q9HBW0 3/20 0.57
LPAR3 Q9UBY5 3/20 0.57
ENPP2 Q13822 3/20 0.57
LPAR6 P43657 2/20 0.57
CES2 O00748 1/20 0.49
TRPV1 Q8NER1 1/20 0.49
PGK1 P00558 1/20 0.48
PGK2 P07205 1/20 0.48
PGD P52209 4/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2935219 1.00 LPAR1 (0.57) LPAR1LPAR5LPAR4LPAR2LPAR3
SCHEMBL19485403 0.83 LPAR1 (0.42) LPAR1LPAR5LPAR4LPAR2LPAR3
SCHEMBL304203 0.82 TDP1 (0.54)
SCHEMBL1286423 0.82 PGK1 (0.58) LPAR1LPAR5LPAR4LPAR2LPAR3
SCHEMBL4572553 0.82 P2RY10 (0.43) LPAR1LPAR5LPAR4LPAR2LPAR3
SCHEMBL9175087 0.82 TSHR (0.52) LPAR1LPAR5LPAR4LPAR2LPAR3
SCHEMBL15385433 0.82 P2RY10 (0.46) LPAR1LPAR5LPAR4LPAR2LPAR3
SCHEMBL19960604 0.81 LPAR1 (0.67) LPAR1LPAR5LPAR4LPAR2LPAR3
SCHEMBL14823175 0.79 P2RY10 (0.47) LPAR1LPAR5LPAR4LPAR2LPAR3
SCHEMBL10623420 0.78 LPAR1 (0.47) LPAR1LPAR5LPAR4LPAR2LPAR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160361914-A1 METHOD FOR PROCESSING ON-PRESS DEVELOPMENT-TYPE LITHOGRAPHIC PRINTING PLATE PRECURSOR AND PRINTING METHOD FUJIFILM CORPORATION (JP) 2016-12-15 US disclosed
US-20160144648-A1 LITHOGRAPHIC PRINTING PLATE PRECURSOR AND METHOD FOR PRODUCING SAME FUJIFILM CORPORATION (JP) 2016-05-26 US disclosed
US-9192818-B2 Golf ball resin composition and golf ball DUNLOP SPORTS CO. LTD. (JP) 2015-11-24 US disclosed
US-20130303466-A1 Chemosensory Receptor Ligand-Based Therapies ELCELYX THERAPEUTICS, INC. (US) 2013-11-14 US disclosed
US-20130303466-A1 Chemosensory Receptor Ligand-Based Therapies ELCELYX THERAPEUTICS, INC. (US) 2013-11-14 US disclosed
US-20130012335-A1 GOLF BALL RESIN COMPOSITION AND GOLF BALL DUNLOP SPORTS CO., LTD. (US) 2013-01-10 US disclosed
WO-2012054527-A2 CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES ELCELYX THERAPEUTICS, INC. (US) 2012-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303466-A1 Chemosensory Receptor Ligand-Based Therapies GPR119, TAS1R2, TAS2R1 LPAR1 149/4885LPAR5 187/4885LPAR4 168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.